fluoxetine has been researched along with Bone Fractures in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures." | 9.41 | Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021) |
| "The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures." | 5.41 | Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021) |
| "Based on available RCTs of fluoxetine and citalopram, SSRIs used for 6 months doubled the risk of fractures in stroke survivors." | 5.12 | Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. ( Almeida, OP; Hankey, GJ; Jones, JS; Kimata, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hankey, GJ | 2 |
| Hackett, ML | 1 |
| Almeida, OP | 2 |
| Flicker, L | 1 |
| Mead, GE | 1 |
| Dennis, MS | 1 |
| Etherton-Beer, C | 1 |
| Ford, AH | 1 |
| Billot, L | 1 |
| Jan, S | 1 |
| Lung, T | 1 |
| Lundström, E | 1 |
| Sunnerhagen, KS | 1 |
| Anderson, CS | 1 |
| Thang-Nguyen, H | 1 |
| Gommans, J | 1 |
| Yi, Q | 1 |
| Jones, JS | 1 |
| Kimata, R | 1 |
| Ceylan, ME | 1 |
| Maner, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluoxetine and Bone Fractures
| Article | Year |
|---|---|
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.
Topics: Citalopram; Depression; Fluoxetine; Fractures, Bone; Humans; Selective Serotonin Reuptake Inhibitors | 2021 |
2 trials available for fluoxetine and Bone Fractures
| Article | Year |
|---|---|
Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.
Topics: Accidental Falls; Affect; Aged; Cognition; Double-Blind Method; Fatigue; Female; Fluoxetine; Fractur | 2021 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
1 other study available for fluoxetine and Bone Fractures
| Article | Year |
|---|---|
Long-term use of fluoxetine and multiple skeleton fractures.
Topics: Adult; Female; Fluoxetine; Fractures, Bone; Humans; Selective Serotonin Reuptake Inhibitors | 2010 |